Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Haematologica

Volumn 99, Issue 7, 2014, Pages 1204-1211

  Hughes, Timothy P ^a,b   Hochhaus, Andreas ^c   Kantarjian, Hagop M ^d   Cervantes, Francisco ^e   Guilhot, François ^f   Niederwieser, Dietger ^g   Le Coutre, Philipp D ^h   Rosti, Gianantonio ⁱ   Ossenkoppele, Gert ^j   Lobo, Clarisse ^k   Shibayama, Hirohiko ^l   Fan, Xiaolin ^m   Menssen, Hans D ^m   Kemp, Charisse ^m   Larson, Richard A ⁿ   Saglio, Giuseppe ^o  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Centre for Cancer Biology and Department of Haematology   (Australia)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k HEMORIO   (Brazil)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GLUCOSE; IMATINIB; NILOTINIB; PHOSPHORUS; TRIACYLGLYCEROL LIPASE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ALLERGY; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DEATH; DEPRESSION; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FEVER; FOLLOW UP; HEADACHE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PROTHROMBIN TIME; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; LEUKEMIA, MYELOID, CHRONIC-PHASE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG SUBSTITUTION; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84903604018     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.091272     Document Type: Article

References (23)

1. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell. 2005;7(2):129-41.
2. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9.
3. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51.
4. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197-203.
5. Novartis Pharmaceuticals Corporation. Tasigna prescribing information. 2012.
6. Novartis Europharm Limited. Tasigna summary of product characteristics. 2012.
7. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112(12):4437-44.
8. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51.
9. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, et al. Significance of suboptimal response to imatinib, as defined by the european LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009;115(16):3709-18.
10. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: Implications and management strategies. Cancer. 2012; 118(5):1181-91.
11. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009;115(3):551-60.
12. Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann. Hematol. 2010;89(7):725-31.
13. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009;113(10):2154-60.
14. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28(3):424-30.
15. Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, et al. High dose imatinib improves cytogenetic and molecular remissions in pretreated Ph+/BCR-ABL+ CML chronic phase patients: First results from the randomized CELSG phase III CML 11 "ISTAHIT" study Haematologica. 2010; 95(6):908-13.
16. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27(1):107-12.
17. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, et al. Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012;26(5):959-62.
18. le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, et al. Nilotinib in patients with ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012;26(6):1189-94.
19. Nicolini FE, Turkina A, Shen ZX, Gallagher N, Jootar S, Powell BL, et al. Expanding nilotinib access in clinical trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinibresistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer. 2012;118(1):118-26.
20. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117(4):1141-5.
21. Yeung DT, Osborn M, White DL, Branford S, Kornhauser M, Slader C, et al. Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression-an update of the TIDEL-II trial. Blood. 2011; 118(21):451.
22. Saglio G, Hochhaus A, Guilhot F, Gatterman N, Wang MC, De Souza C, et al. Nilotinib is associated with fewer treatment failures and suboptimal responses vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from ENESTnd. Haematologica. 2011;96(s2):58-9.(Abstract 0145).
23. Cross NCP, White H, Müller MC, Saglio G and Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172-5.